Clinical Trial Update: Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen

View source ↗

Summary

Clinical trial update reporting the completion of a Special Drug-use Surveillance study for Kesimpta (ofatumumab) 20 mg subcutaneous injection pen. Conditions s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing-remitting Multiple Sclerosis, Active Secondary Progressive Multiple Sclerosis | Status: COMPLETED